Welcome to the international HTA database

Showing [21894 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Information for health insurance fund members on prenatal testing]
2015	Institut national d'excellence en sante et en services sociaux (INESSS)	[Information brief concerning palliative care day centres]
2009	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Information and communications technologies in mental health (Telepsychiatry)]
2009	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Information and communications technologies in CHF management programmes. Organizational challenges and evidence status]
2008	Committee for New Health Technology Assessment (CNHTA)	[Influenza virus A & B, RT-nested PCR]
2021	Health Council of the Netherlands Gezondheidsraad (GR)	[Influenza vaccination: review of indications]
2000	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Influenza vaccination of the elderly (funded by DIHTA)]
2022	Canary Health Service	[Influenza vaccination in children 6 to 59 months of age]
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Influence of an existing health care plan aimed at managing ST-elevation myocardial infarction on the waiting time until re-perfusion, and types of re-perfusion. Pilot study]
2007	Unit of Health Economics and Technology Assessment in Health Care (HunHTA)	[Infliximab in patients with arthritis psoriatic: systematic review of the clinical and economic literature]
2004	Unit of Health Economics and Technology Assessment in Health Care (HunHTA)	[Infliximab (REMICADE) in patients with rheumatoid arthritis; systematic review of the clinical and economic literature]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Inebilizumab (neuromyelitis optica spectrum disorders [NMOSD]) - Benefit assessment according to § 35a SGB V]
2010	The Netherlands Organisation for Health Research and Development (ZonMw)	[Induction of labour versus expectant management in women with preterm premature rupture of membranes between 34 and 37 weeks (PPROMEXIL-study)]
2012	The Regional Health Technology Assessment Centre (HTA-centrum)	[Induction of labour at 41 completed until 42 completed gestational weeks, update of mini-HTA VGR 2007]
2019	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Induction immunosuppressive therapy in patients undergoing heart transplantation]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Induced sputum in severe asthma patients]
2013	Basque Office for Health Technology Assessment (OSTEBA)	[Individualised multidisciplinary care programme in frail patients (PAMI)]
2011	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Individual health services]
2010	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Indirect comparisons of therapeutic interventions]
2014	National Evidence-based Healthcare Collaborating Agency (NECA)	[Indirect comparison methodology research for health technology assessment: Comparison of drug treatment effect in adult attention deficit hyperactivity disorder using a common comparator]
2019	Basque Office for Health Technology Assessment (OSTEBA)	[Indications, utility and use of ultrasound in primary care]
2011	Institut national d'excellence en sante et en services sociaux (INESSS)	[Indications for positron emission tomography (pet): a brief update]
2008	Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)	[Indications for hyperbaric oxygen therapy: update]
2012	Basque Office for Health Technology Assessment (OSTEBA)	[Indications and recommendations for the use of PET-CT in the planning of radiation oncology treatment. Systematic review]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Indicaterol/glycopyrronium - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2024	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Indicated prevention of suicide in children and adolescents]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Benefit assessment according to §35a Social Code Book V]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Addendum to Commission A20-69]
2010	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Increase of physical activity in essential hypertension - Rapid report]
2023	Health Sciences Institute in Aragon (IACS)	[Incorporation of expanded genetic analysis to assist the assessment of venous thromboembolism risks and recurrent spontaneous miscarriages]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Inclusion of new health technologies into Spanish hospitals]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Inclisiran (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V]
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Incidence of errors in intensive care: effects of increased awareness and of improved communication by the introduction of explicit daily goals]
2006	Basque Office for Health Technology Assessment (OSTEBA)	[Incidence of diabetic retinopathy based on a screening programme using a non-mydriatic retinal camera on diabetic patients in the Autonomous Community of the Basque Country]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[In-toto thrombectomy using a retriever/aspiration system for acute pulmonary artery embolism - Addendum to commission H22-04]
2009	Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)	[In vitro fertilization: comparative profile of European and Oceania countries]
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Improving the efficiency and quality of follow-up after curative treatment for breast cancer]
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Improving the early diagnosis of myocardial infarction in primary care: the added value of a rapid assay to detect heart-type FABP, a novel marker of cardiac injury]
2009	Basque Office for Health Technology Assessment (OSTEBA)	[Improving the care of elderly patients with chronic pathologies]
2008	The Netherlands Organisation for Health Research and Development (ZonMw)	[Improving lifestyle adherence in patients with high risk for cardiovascular diseases in general practice. Costs and effects of patient involvement in cardiovascular risk management]
2007	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementing a routine outcome monitoring system to study the effectiveness of long-term psychoanalytic treatment and therapeutic decision making in four cohorts of personality disordered and/ or recurrent or chronic depressive patients]
2008	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of the WIP guideline 'Prevention of infections due to urethral bladder catheterization']
2010	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of structural feedback by means of perinatal audit to caregivers in cases of perinatal mortality in the northern part of the Netherlands (IMPACT)]
2010	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of selective karyotyping in couples with recurrent miscarriage]
2012	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of screening and treatment of high-risk fracture patients by an osteoporosis nurse-practitioner]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Implementation of quality indicators to assess the high risk of colorectal cancer clinic]
2012	The Swedish Council on Health Technology Assessment (SBU)	[Implementation of psychiatric guidelines and evidence-based knowledge in the primary care sector]
2008	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of outpatient schema focused therapy for borderline personality disorder in three settings: general community mental health centers, forensic centers and addiction treatment centers]
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of intensive insulin therapy (IIT) in critically ill patients, targeting at normoglycemia while preventing hypoglycemia]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Implementation of guidelines - obstructive and beneficial factors]
2007	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of evidence-based guidelines for appropriate use of ultrasonography in diagnostic breast imaging: the MAMMOED-2 study]
2007	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of an evidence based smoking cessation strategy (SMOCC) for patients with COPD in primary care]
2007	The Netherlands Organisation for Health Research and Development (ZonMw)	[IMPlementation of a prediction rule in Anesthesia practice to improve Cost-effectiveness of Treatment of postoperative nausea and vomiting: the IMPACT trial]
2008	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of a new cost-effective treatment (HIT) for patients with therapy refractory auditory hallucinations]
2012	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of a multiple intervention aimed at optimising prescription of antibiotics for respiratory tract infections, embedded within the new practice accreditation of the Dutch College of General Practitioners; a randomized controlled trial]
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Implementation and development of a treatment programme for peritoneal carcinomatosis in Catalonia. Indications and clinical results using Sugarbaker's technique]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Implantation via injection under endoscopic ultrasound guidance of 32P-labeled microparticles for unresectable, locally advanced pancreatic tumours]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Implantation via injection under endoscopic ultrasound guidance of 32P-labeled microparticles for unresectable, locally advanced pancreatic tumours - Addendum to commission H21-13]
2009	Committee for New Health Technology Assessment (CNHTA)	[Implantation technology of autologous chondrocyte using fibrin]
2014	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Implantation of a permanent embolic protection in patients with non-valvular attrial fibrillation in left auricular appendage]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Implantation of a lumbar artificial endoprosthesis (anuloplasty/anular repair device)]
2012	Institut national d'excellence en sante et en services sociaux (INESSS)	[Implantable ventricular assist devices: assessment of evidence and required elements to establish a clinical registry in Québec]
2022	Canary Health Service	[Implantable neurostimulation device for the treatment of drug-resistant pediatric epilepsy]
2008	Committee for New Health Technology Assessment (CNHTA)	[Implantable drug infusion pump implantation]
2024	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Implantable devices for left atrial appendage closure. Monitoring study]
1999	Andalusian Health Technology Assessment Area (AETSA)	[Implantable defibrillators: criteria for clinical indications and decision making on coverage - non-systematic review]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Implantable cardiac monitors in syncope of unknown etiology]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Implantable cardiac defibrillator for primary prevention of sudden death]
2020	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Implantable automatic defibrillator for primary prevention of sudden cardiac death in Spain: efficacy, safety, and efficiency]
2013	Institute for Clinical Effectiveness and Health Policy (IECS)	[Implantable and programmable sacral neuromodulator (Interstim®) treatment of urinary, fecal and combined incontinence]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Implant-supported supraconstructions for the treatment of shortened dental arches]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Impella Recover® 2.5 ventricular assist device]
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Impact of the implementation of EFQM in Osakidetza]
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Impact of the implementation of a population-based cervical cancer screening program based on European recommendations (test/interval) with regard to the current situation]
2010	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Impact of HTA-research in Austria for the health care system. Part 1: Overview - Update]
2012	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Impact of day care centres in monitoring patients with Obstructive Sleep Apnea Syndrome (OSAS)]
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Impact of clinical and health services research in advancing knowledge. Applied study to the CAHTA research calls]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Impact of clinical and health services research in advancing knowledge. Applied study to the CAHTA research calls (second edition)]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Impact of clinical and health services research calls on informing decision-making and capacity building. The viewpoint of the researchers]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Impact of a prioritization system for patients on waiting list for hip and knee arthroplasties and cataract surgery]
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Impact from HTA-research for the Austrian health care system. Part 2: Results of the empirical survey]
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Impact evaluation of optimal use guidelines implementation for self-monitoring of blood glucose by adult patients with type 2 diabetes and not using insulin]
2018	Basque Office for Health Technology Assessment (OSTEBA)	[Immunological faecal occult blood test for patients with symptoms compatible with colorectal cancer: recommendation of Clinical Practice Guides and use in the National Health System]
2009	The Regional Health Technology Assessment Centre (HTA-centrum)	[Immunoglobulin in patients with post-polio syndrome]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Immunoglobulin in chronic inflammatory demyelinating polyneuropathy and other neurological conditions]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Immunoglobulin for myasthenia gravis chronic treatment]
2010	Andalusian Health Technology Assessment Area (AETSA)	[Immunogenicity and safety of prepandemic vaccines against H5N1 avian flu]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Immunocyanin in urothelial bladder cancer
2012	Institut national d'excellence en sante et en services sociaux (INESSS)	[Immunochemical fecal occult blood. Determination of a positivity threshold for the upcoming demonstration projects under Québec's colorectal cancer screening program]
2010	Andalusian Health Technology Assessment Area (AETSA)	[Immunisation against angiotensin II. A therapeutic vaccine against arterial hypertension]
2005	Unidad de Evaluacion de Tecnologias Sanitarias (UETS)	[Immediate breast reconstruction. Systematic review and evaluation of results in a RMI unit in the Community of Madrid]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Imlifidase (kidney transplantation) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Imipenem/cilastatin/relebactam (bacterial infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2005	Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS )	[Imatinib in the treatment of chronic myelogenous leukemia]
2005	Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS )	[Imatinib for gastro-intestinal stromal tumors]
2013	The Regional Health Technology Assessment Centre (HTA-centrum)	[Image-guided system for endoscopic sinus surgery]
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Image-guided spinal fusion technology]
2012	Institute for Clinical Effectiveness and Health Policy (IECS)	[Image-guided radiosurgery and radiotherapy for central nervous systems tumors]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Image-guided radiation therapy in liver and lung tumors]
2009	Committee for New Health Technology Assessment (CNHTA)	[IL2RG gene mutation analysis]